Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tablets
- Posted on June 10, 2026
- By Business News Today
- 0 Views
- 1 min read
Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tablets
Concord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approval for rheumatoid arthritis and other conditions is expected to bolster its U.S. market presence and product portfolio, targeting a $500 million market opportunity.
